Develops drugs for blood cancers and disorders.
Jun 2026Revenue $277M/yrExpenses $190M/yr
Reached break-even Aug 2024
Figures by year
When did Rigel Pharmaceuticals become profitable?
Its revenue passed its expenses in Aug 2024. In the 12 months to Jun 2026, revenue was $277M and expenses $190M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $294M | $169M | $125M |
| Dec 2024 | $179M | $155M | $24.2M |
| Dec 2023 | $117M | $137M | −$20.5M |
| Dec 2022 | $120M | $176M | −$55.5M |
| Dec 2021 | $149M | $162M | −$12.5M |
| Dec 2020 | $109M | $138M | −$29.0M |
| Dec 2019 | $59.3M | $128M | −$69.1M |
| Dec 2018 | $44.5M | $117M | −$72.7M |
| Dec 2017 | $4.48M | $84.1M | −$79.6M |
| Dec 2016 | $20.4M | $90.1M | −$69.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.